Dr Lalchandani Labs Share Price
7.64-0.40 (-4.98%)
-60.23% past 1 Year
Dr Lalchandani Labs Limited is a provider of diagnostic and related healthcare tests and services in Delhi/NCR. Through their integrated network, it offers patients and healthcare providers a broad range
Corporate filings & documents
Announcements
Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations for quarter ended June 2026
1 month agoCompliance Certificate under Regulation 74(5) of SEBI (DP) Regulations for quarter ended June 2026
1 month agoAudited Financial Results for the quarter and year ended March 31 2026
3 months agoAudited Financial Results for the quarter and year ended March 31 2026
3 months agoAudited Financial Results for the half year and year ended March 31 2206
3 months agoAudited Financial Results for the half year and year ended March 31 2206
3 months agoIntimation of Postponement and Rescheduling of Board Meeting scheduled to be held on Today May 30 2026.
3 months agoWe are pleased to inform that the Company has successfully opened a new strategic Centre at Dwarka New Delhi.
3 months agoDr Lalchandani Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 inter alia to consider and approve financial results of the Company for Half year and Year ended March 31 2026
3 months ago<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr> <td>1</td> <td>Name of Company</td> <td>Dr Lalchandani Labs Ltd</td> </tr> <tr> <td>2</td> <td>CIN NO.</td> <td>L85320DL2017PLC321605</td> </tr> <tr> <td>3</td> <td>Report filed for FY</td> <td>2025-2026</td> </tr> <tr><td colspan=3>Details of the Current block (all figures in Rs crore):</td><tr> <tr> <td>4</td> <td>2 - year block period (Specify financial years)* </td> <td>2024-2025 2025-2026</td> </tr> <tr> <tr> <td>5</td> <td>Incremental borrowing done in FY (T)(a) </td> <td>0.00</td> </tr> <tr> <td>6</td> <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td> <td>0.00</td> </tr> <tr> <td>7</td> <td>Actual borrowing done through debt securities in FY (T)(c)</td> <td>0.00</td> </tr> <tr> <td>8</td> <td> Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d)</td> <td>0</td> </tr> <tr> <td>8</td><td>Quantum of (d) which has been met from (c)(e)*</td> <td>0</td> </tr><tr> <td>9</td><td> Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}*</td> <td>0</td> </tr> </table> <br/><br/><table><tr><td colspan=2><b>Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>2024-2025 2025-2026</td></tr> <tr><td>Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#</td><td>0.00</td></tr> </table> <div> <br/><br/><br/> <table><tr><td>Name of the Company Secretary :-</td><td>NA</td></tr><tr><td>Designation :-</td><td>NA</td></tr> <tr><td>Name of the Chief Financial Officer :- </td><td>Anchal Gupta</td></tr> <tr><td>Designation : -</td><td>Chief Financial Officer</td></tr></table><div> <br/> Date: 04/05/2026<br/><br/></div>
4 months ago<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr> <td>1</td> <td>Name of Company</td> <td>Dr Lalchandani Labs Ltd</td> </tr> <tr> <td>2</td> <td>CIN NO.</td> <td>L85320DL2017PLC321605</td> </tr> <tr> <td>3</td> <td>Report filed for FY</td> <td>2025-2026</td> </tr> <tr><td colspan=3>Details of the Current block (all figures in Rs crore):</td><tr> <tr> <td>4</td> <td>2 - year block period (Specify financial years)* </td> <td>2024-2025 2025-2026</td> </tr> <tr> <tr> <td>5</td> <td>Incremental borrowing done in FY (T)(a) </td> <td>0.00</td> </tr> <tr> <td>6</td> <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td> <td>0.00</td> </tr> <tr> <td>7</td> <td>Actual borrowing done through debt securities in FY (T)(c)</td> <td>0.00</td> </tr> <tr> <td>8</td> <td> Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d)</td> <td>0</td> </tr> <tr> <td>8</td><td>Quantum of (d) which has been met from (c)(e)*</td> <td>0</td> </tr><tr> <td>9</td><td> Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}*</td> <td>0</td> </tr> </table> <br/><br/><table><tr><td colspan=2><b>Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>2024-2025 2025-2026</td></tr> <tr><td>Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#</td><td>0.00</td></tr> </table> <div> <br/><br/><br/> <table><tr><td>Name of the Company Secretary :-</td><td>NA</td></tr><tr><td>Designation :-</td><td>NA</td></tr> <tr><td>Name of the Chief Financial Officer :- </td><td>Anchal Gupta</td></tr> <tr><td>Designation : -</td><td>Chief Financial Officer</td></tr></table><div> <br/> Date: 04/05/2026<br/><br/></div>
4 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Dr Lalchandani Labs Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L85320DL2017PLC321605</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>Nil</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: NA <br/> Designation: NA <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Anchal Gupta <br/> Designation: Chief FInancial Officer <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 30/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Dr Lalchandani Labs Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L85320DL2017PLC321605</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>Nil</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: NA <br/> Designation: NA <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Anchal Gupta <br/> Designation: Chief FInancial Officer <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 30/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
4 months agoResignation of Mrs. Saniya Hussain from the position of Company Secretary and Compliance Officer
4 months agoResignation of Mrs. Saniya Hussain from the position of Company Secretary and Compliance Officer
4 months agoReply to the clarification sought by exchange dated April 13 2026
4 months agoReply to the clarification sought by exchange dated April 13 2026
4 months agoThe Exchange has sought clarification from Dr Lalchandani Labs Ltd on April 13 2026 with reference to significant movement in price in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.<BR><BR>The reply is awaited.
4 months agoCertificate under Regulation 74(5) of SEBI DP Regulations for Quarter ended March 2026
4 months agoCertificate under Regulation 74(5) of SEBI DP Regulations for Quarter ended March 2026
4 months agoTrading Window Closure for March 31 2026
5 months agoTrading Window Closure for March 31 2026
5 months agopost issue newspaper advertisements under Regulation 92
6 months agopost issue newspaper advertisements under Regulation 92
6 months agoThe Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Anuraag Gambhir
6 months agoThe Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Anuraag Gambhir
6 months agoApproval of basis of allotment under Right issue
6 months agoBoard meeting for approval of basis of allotment for right issue
6 months agoNewspaper publication for extension of issue closing date and extension of date of on market renunciation of Rights Entitlements.
6 months agoNewspaper publication for extension of issue closing date and extension of date of on market renunciation of Rights Entitlements.
6 months agoWe wish to inform you that the Board of Directors of the Company considered and approved the extension of closing date of the ongoing right issue. The issue has been extended to February 27 2026 from the earlier issue closing date February 20 2026
6 months agoWe wish to inform you that the Board of Directors of the Company considered and approved the extension of closing date of the ongoing right issue. The issue has been extended to February 27 2026 from the earlier issue closing date February 20 2026
6 months agoThis is in reference to the Outcome of the Meeting of Board of Directors dated January 20 2026 we wish to inform you that the Board of Directors of Dr Lalchandani Labs Limited at its meeting held on today i.e. February 16 2026 has considered and approved the extension of the closing date of the ongoing rights issue.The Rights Issue which opened on Wednesday February 04 2026 and originally scheduled to close on Friday February 20 2026 has now been extended until Friday February 27 2026. The extension has been granted to facilitate better participation from eligible shareholders and to provide them with adequate time to subscribe to the Rights Issue.
6 months agoThis is in reference to the Outcome of the Meeting of Board of Directors dated January 20 2026 we wish to inform you that the Board of Directors of Dr Lalchandani Labs Limited at its meeting held on today i.e. February 16 2026 has considered and approved the extension of the closing date of the ongoing rights issue.The Rights Issue which opened on Wednesday February 04 2026 and originally scheduled to close on Friday February 20 2026 has now been extended until Friday February 27 2026. The extension has been granted to facilitate better participation from eligible shareholders and to provide them with adequate time to subscribe to the Rights Issue.
6 months agoCorrigendum to the newspaper publication dated January 31 2026
7 months agoNewspaper publication as per stated regulation
7 months agoPlease find enclosed the soft copy of Letter of Offer dated January 20 2026 for the Rights Issue of Dr Lalchandani Labs Limited. The Company is also submitting this Letter of Offer with Securities and Exchange Board of India (SEBI) for its information in compliance with SEBI (Issue of Capital and Disclosure Requirements) Regulations 2018 as amended and SEBI Circular bearing no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2025/31 dated March 11 2025.
7 months agontimation of Record Date pursuant to Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations)
7 months agoIn continuation of our earlier intimation dated December 16 2025 and subsequent deferment notice dated December 22 2025 we wish to inform you that the meeting of the Board of Directors of Dr Lalchandani Labs Limited (the Company) was duly held today i.e. Tuesday January 20 2025 to consider and approve matters relating to the proposed Rights Issue of Equity Shares of the Company.
7 months agoIn continuation of our earlier intimation dated December 16 2025 and subsequent deferment notice dated December 22 2025 we wish to inform you that the meeting of the Board of Directors of Dr Lalchandani Labs Limited (the Company) was duly held today i.e. Tuesday January 20 2025 to consider and approve matters relating to the proposed Rights Issue of Equity Shares of the Company.
7 months agoIn continuation of our earlier intimation dated December 16 2025 and subsequent deferment notice dated December 22 2025 we wish to inform you that the meeting of the Board of Directors of Dr Lalchandani Labs Limited (the Company) was duly held today i.e. Tuesday January 20 2025 to consider and approve matters relating to the proposed Rights Issue of Equity Shares of the Company.
7 months agoWe are pleased to inform that the company has received the In-principle approval from BSE Limited for Rights issue of Equity Shares the letter is enclosed
7 months agoCompliance Certificate under Regulation 74(5) for Quarter ended December 31 2025
7 months agoThis is with reference to our prior intimation dated December 16 2025 wherein we had informed the Exchange about the meeting of the Board of Directors of Dr Lalchandani Labs Limited (the Company) scheduled to be held on Monday December 22 2025 inter alia to consider and approve matters relating to the proposed Rights Issue including fixation of the record date issue price entitlement ratio and other related terms.We wish to inform you that the aforesaid Board Meeting scheduled to be held on December 22 2025 has been deferred due to the non-receipt of In-Principle Approval from BSE Limited for the proposed Rights Issue.
8 months agoDr Lalchandani Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/12/2025 inter alia to consider and approve fixation of the record date;? determination of the issue price;? determination of the rights entitlement ratio; and? such other terms and conditions as may be required in accordance with applicable laws subject to receipt of necessary statutory and regulatory approvals.
8 months agoBoard of Directors in the Board Meeting held today has approved the raising of fund by way of right issue to the eligible equity shareholders as on record date (to be determined and specified subsequently)
8 months agoRaising of funds through the issuance of equity shares of face value ?10 each by way of rights issue for an amount not exceeding Rs 433.31 Lakhs to the eligible equity shareholders of the Company as on the record date (to be determined and notified subsequently) subject to receipt of statutory / regulatory approvals in accordance with the amended SEBI (Issuer of Capital and Disclosure Requirements) Amendment Regulations 2025 (the "SEBI ICDR Regulations") and other applicable regulations and subject to necessary approvals as may be required.
8 months agoOutcome of Board Meeting
8 months agoDr Lalchandani Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/12/2025 inter alia to consider and approve raising of funds through a rights issue and/or any other permissible mode
9 months agoUnaudited Financial Results for the half year ended September 2025
9 months agoAnnual reports
Concalls & investor presentations
No presentations found
Corporate Actions
Date
Type
Details
2026-01-27
Rights
1:1;10.0
Company details
Registered office
M-20, 19 C, Club Road Greater Kailash Part-1, Punjabi Bagh New Delhi Delhi PIN: 110048 Tel No: 011-49057058-9 / 8010689689 Fax No: NULL Email: [email protected] Internet: www.lalchandanipathlab.com
Registrars
Subramanian Buildings No 1 , Club House Road,,Chennai Subramanian Buildings No 1 Club House Road NULL PIN: Tel No: 044-28460390/28460394 Fax No: 044-28460129 Email: NULL
Management
Arjan Lalchandani, Chairman & Managing Director
Arjan Lalchandani, Chairman & Managing Director
Mohit Lalchandani, Whole Time Director & Chief Executive Officer
Anchal Gupta, Executive Director & Chief Financial Officer
Swati Chandra, Non Executive Director
Rajiv Handa, Non Executive Independent Director
Mohan Lal Gandhi, Non Executive Independent Director
Details
BSE 541299
NSE NULL
ISIN INE871Z01013